Compare CAG & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAG | GKOS |
|---|---|---|
| Founded | 1919 | 1998 |
| Country | United States | United States |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.0B |
| IPO Year | 1994 | 2015 |
| Metric | CAG | GKOS |
|---|---|---|
| Price | $15.75 | $104.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $18.86 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 13.6M | 598.4K |
| Earning Date | 04-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 8.90% | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,500,000,000.00 | $507,442,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $27.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $15.04 | $73.16 |
| 52 Week High | $27.68 | $130.23 |
| Indicator | CAG | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 45.83 |
| Support Level | N/A | $81.54 |
| Resistance Level | $19.54 | $104.66 |
| Average True Range (ATR) | 0.52 | 4.10 |
| MACD | -0.05 | 0.57 |
| Stochastic Oscillator | 32.39 | 61.22 |
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.